Start-Up Quarterly Statistics, Q1 2008
This article was originally published in Start Up
Executive Summary
Start-Up analyzes fundraising and alliances among start-ups in the biopharmaceutical, medical device and in vitro diagnostics segments from January through March 2008. Data comes from Windhover’s Strategic Transactions Database.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2008
Start-Up analyzes fundraising and alliances among emerging companies in the biopharmaceutical, medical device and in vitro diagnostics segments from April through June 2008. Data comes from Windhover's Strategic Transactions Database.
Start-Up Quarterly Statistics, Q2 2008
Start-Up analyzes fundraising and alliances among emerging companies in the biopharmaceutical, medical device and in vitro diagnostics segments from April through June 2008. Data comes from Windhover's Strategic Transactions Database.
Cannasat Therapeutics Inc.
Admit it, you inhaled. It's comments like that that greet David Hill, co-founder and CEO of Cannasat Therapeutics, a Toronto-based company seeking to exploit cannabinoid receptor-targeting drugs including THC (delta-9-tetrahydrocannabinol), the psychoactive component in marijuana (cannabis). However, the laughing ceases once he starts talking about the evidence of the effectiveness of cannabis-derived compounds in treating the symptoms associated with such conditions such as pain, multiple sclerosis, HIV/AIDS, cancer, mood disorders, glaucoma, and many others.